HELIXMITH
LIVE

Serial Number

79300661

Owner

HELIXMITH CO., LTD

Attorney

Daniel P. Mullarkey

Filing Date

Nov 11, 2020

Add to watchlist:

No watchlists yet
View on USPTO

HELIXMITH Trademark

Serial Number: 79300661 • Registration: 6541689

HELIXMITH is a trademark filed by HELIXMITH CO., LTD on November 11, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

HELIXMITH CO., LTD (5 trademarks)

1 GWANAK-RO 5TH FL. BLDG. 203
SEOUL 08826 , KR

Entity Type: 03

Trademark Details

Filing Date

November 11, 2020

Registration Date

November 2, 2021

Published for Opposition

August 17, 2021

Goods & Services

Pharmaceutical preparations for health care for treating neurological diseases, muscular diseases, ischemic diseases, renal diseases, cancer, inflammatory diseases, allergy, respiratory diseases, urologic diseases, cardiovascular diseases, menopause symptoms, or immune system related diseases; Crude medicines for treating neurological diseases, inflammatory diseases, allergy, respiratory diseases, urologic diseases, cardiovascular diseases, menopause symptoms, or immune system related disease; Pharmaceutical preparations extracted from crude medicine for treating neurological diseases, inflammatory diseases, allergy, respiratory diseases, urologic diseases, cardiovascular diseases, menopause symptoms, or immune system related diseases; reagents for use in veterinary genetic testing; dietary supplement drinks; dietary supplements; chemical preparations for pharmaceutical purposes for treating chemical imbalances; Gene therapy preparations for treating neurological diseases, muscular diseases, ischemic diseases, renal diseases, or cancer; Drugs for medical purposes for treating neurological diseases, muscular diseases, ischemic diseases, renal diseases, cancer, inflammatory diseases, allergy, respiratory diseases, urologic diseases, cardiovascular diseases, menopause symptoms, or immune system related diseases; chemical preparations for use in dna analysis for medical diagnostic purposes; Biological preparations for medical for veterinary purposes for treating neurological diseases, muscular diseases, ischemic diseases, renal diseases, or cancer; reagents for use in medical genetic testing; Pharmaceutical drugs for treating neurological diseases, muscular diseases, ischemic diseases, renal diseases, cancer, inflammatory diseases, allergy, respiratory diseases, urologic diseases, cardiovascular diseases, menopause symptoms, or immune system related diseases; Medicines for human purposes for treating neurological diseases, muscular diseases, ischemic diseases, renal diseases, cancer, inflammatory diseases, allergy, respiratory diseases, urologic diseases, cardiovascular diseases, menopause symptoms, or immune system related diseases; Pharmaceutical preparations for diagnosis for cancer or renal diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders; Ethical medicinal preparations for the treatment of neurological diseases, muscular diseases, ischemic diseases, renal diseases, cancer, inflammatory diseases, allergy, respiratory diseases, urologic diseases, cardiovascular diseases, menopause symptoms, or immune system related diseases; nutraceutical preparations for therapeutic or medical purposes; Therapeutic drugs and agents for the treatment of neurological diseases, muscular diseases, ischemic diseases, renal diseases, cancer, inflammatory diseases, allergy, respiratory diseases, urologic diseases, cardiovascular diseases, menopause symptoms, or immune system related diseases; health functional food being dietetic foods mainly based on Korean herbal medicines

Retail store services featuring reagents for use in veterinary genetic testing; retail store services featuring chemical preparations for pharmaceutical purposes; wholesale store services featuring gene therapy preparations; retail store services featuring gene therapy preparations; retail services by direct solicitation by sales agents in the field of gene therapy preparations; retail store services featuring chemical preparations for use in DNA analysis for medical purposes; retail store services featuring biological preparations for medical or veterinary purposes; retail store services featuring drugs for medical purposes; retail store services featuring reagents for use in medical genetic testing; retail store services featuring pharmaceutical preparations for diagnosis; retail store services featuring pharmaceutical preparations for the treatment of immune system related diseases and disorders; retail store services featuring ethical medicinal preparations; wholesale store services featuring therapeutic drugs and agents; retail store services featuring therapeutic drugs and agents

Research and development of vaccines and medicines; biotechnological research; development of new products for others in the field of biotechnology; scientific research in the fields of biomedicine; Scientific research and chemical testing services in the fields of bacteriology and virology; drug discovery services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical products development; consultancy relating to pharmaceutical research and development; pharmaceutical research and development; pharmaceutical research services; research of pharmaceuticals; consultancy in analysis of biology sequence processing for medical research purposes; consultancy in analysis of genomics for medical research purposes; scientific research in the fields of medicine, health and pharmacology; analysis of human serum for medical research; analysis of human tissues for medical research; blood analysis services

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
May 16, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 25, 2022 FICS
FINAL DISPOSITION PROCESSED
Apr 25, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 2, 2022 FICR
REGISTERED-PRINCIPAL REGISTER
Nov 2, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 17, 2021 NPUB
PUBLISHED FOR OPPOSITION
Aug 17, 2021 PUBO
NOTIFICATION PROCESSED BY IB
Aug 15, 2021 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jul 28, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jul 28, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 28, 2021 NONP
ASSIGNED TO LIE
Jul 14, 2021 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 14, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 13, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 13, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 13, 2021 TROA
REFUSAL PROCESSED BY IB
May 17, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 27, 2021 RFCS
REFUSAL PROCESSED BY MPU
Apr 27, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 24, 2021 RFCR
NON-FINAL ACTION WRITTEN
Apr 23, 2021 CNRT
ASSIGNED TO EXAMINER
Apr 21, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 1, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 28, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 24, 2020 REPR